Terms: = Kidney tumors AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Treatment
18 results:
1. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
[No Abstract] [Full Text] [Related]
2. Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Sahetia KM; Dave VN; Pal M; Menon S
Indian J Cancer; 2023 Oct; 60(4):575-577. PubMed ID: 38145907
[TBL] [Abstract] [Full Text] [Related]
3. treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P; Grandal B; Jochum F; Bihan K; Coussy F; Barraud S; Asselain B; Dumas E; Sebbag C; Hotton J; Spaggiari E; Pierga JY; Savarino R; Laas E; Spano JP; Reyal F; Hamy AS
JAMA Netw Open; 2023 Oct; 6(10):e2339934. PubMed ID: 37883083
[TBL] [Abstract] [Full Text] [Related]
4. Metastases to the kidney from primary lung cancer : clinicopathological analysis of six cases in a single center.
Lian H; Pan X; Hong B; Min J; Huang F
Diagn Pathol; 2023 May; 18(1):60. PubMed ID: 37161448
[TBL] [Abstract] [Full Text] [Related]
5. [Papillary renal neoplasm with reverse polarity: a clinicopathological analysis].
Ji RH; Wang XT; Li R; Ye SB; Wang X; Ma HH; Lu ZF; Rao Q; Xia QY
Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):23-27. PubMed ID: 34979749
[No Abstract] [Full Text] [Related]
6. [Clinicopathological analysis of lung metastatic tumor].
Lou N; Niu YR; Yang F; Lu ZH
Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1039-1044. PubMed ID: 34496496
[No Abstract] [Full Text] [Related]
7. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.
Tatjana A; Tjota MY; O'Donnell PH; Eggener SE; Agarwal PK; Haridas R; Segal J; Wang P
Virchows Arch; 2022 Feb; 480(2):487-492. PubMed ID: 34128116
[TBL] [Abstract] [Full Text] [Related]
8. Prospective evaluation of CT-guided hdr brachytherapy as a local ablative treatment for renal masses: a single-arm pilot trial.
Damm R; Streitparth T; Hass P; Seidensticker M; Heinze C; Powerski M; Wendler JJ; Liehr UB; Mohnike K; Pech M; Ricke J
Strahlenther Onkol; 2019 Nov; 195(11):982-990. PubMed ID: 31346674
[TBL] [Abstract] [Full Text] [Related]
9. Ultrasound-assisted catheter placement in CT-guided hdr brachytherapy for the local ablation of abdominal malignancies: Initial experience.
Damm R; El-Sanosy S; Omari J; Damm R; Hass P; Pech M; Powerski M
Rofo; 2019 Jan; 191(1):48-53. PubMed ID: 30308690
[TBL] [Abstract] [Full Text] [Related]
10. Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.
Lee B; Ahn SH; Kim H; Son J; Sung J; Han Y; Huh SJ; Kim JS; Kim DW; Yoon M
J Appl Clin Med Phys; 2016 Sep; 17(5):124-132. PubMed ID: 27685104
[TBL] [Abstract] [Full Text] [Related]
11. gata3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma.
So JS; Epstein JI
Mod Pathol; 2013 Oct; 26(10):1365-70. PubMed ID: 23599157
[TBL] [Abstract] [Full Text] [Related]
12. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.
Hsu IC; Bae K; Shinohara K; Pouliot J; Purdy J; Ibbott G; Speight J; Vigneault E; Ivker R; Sandler H
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):751-8. PubMed ID: 20207506
[TBL] [Abstract] [Full Text] [Related]
13. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment.
Tavares TS; Nanus D; Yang XJ; Gudas LJ
Cancer Biol Ther; 2008 Oct; 7(10):1607-18. PubMed ID: 18769122
[TBL] [Abstract] [Full Text] [Related]
14. Fractionated intraluminal hdr 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries.
Stranzl H; Gabor S; Mayer R; Prettenhofer U; Wurzinger G; Hackl A
Strahlenther Onkol; 2002 Aug; 178(8):442-5. PubMed ID: 12240550
[TBL] [Abstract] [Full Text] [Related]
15. High dose rate intraluminal brachytherapy in the treatment of malignant airway obstructions.
Petera J; Spásová I; Neumanová R; Skricková J; Salajka F; Hrazdírová A; Kaplanová J; Coupková H; Coupek P; Kucera M
Neoplasma; 2001; 48(2):148-53. PubMed ID: 11478697
[TBL] [Abstract] [Full Text] [Related]
16. Perioperative brachytherapy as an additional therapeutic option in patients with renal cell carcinoma (RCC), either inoperable or after completed percutaneous radiotherapy.
Kwiatkowski J; Schmidt B; Merkle P; Keller K
Anticancer Res; 1999; 19(2C):1597-9. PubMed ID: 10365153
[TBL] [Abstract] [Full Text] [Related]
17. Nephrostomy track brachytherapy following percutaneous resection of transitional cell carcinoma of the renal pelvis.
Shepherd SF; Patel A; Bidmead AM; Kellett MJ; Woodhouse CR; Dearnaley DP
Clin Oncol (R Coll Radiol); 1995; 7(6):385-7. PubMed ID: 8590702
[TBL] [Abstract] [Full Text] [Related]
18. hdr intraluminal brachytherapy for lung tumours--a case report.
Wee JT; Yang ET; Lim YC
Singapore Med J; 1994 Jun; 35(3):325-6. PubMed ID: 7527939
[TBL] [Abstract] [Full Text] [Related]
